Keytruda TV advertising This could be one of the reasons for the slippage of the Merck stock. It is frightening as to the magnitude of potential side effects.
When Ruvidar becomes an alternative it likely will compare very favorably on the "Warnings" issue.
Merck is certainly is fully aware of this threat and should or may be formulating a strategy to deal with the issue.